pharmexec.com

CSPC and AstraZeneca form biologics manufacturing JV in Shijiazhuang

CSPC Pharmaceutical Group Limited logoCSPC Pharmaceutical Group Limited
Sig3.48Sen+5.69Env+0.20Soc+0.96Gov+1.79
AstraZeneca logoAstraZeneca
Sig3.75Sen+3.85Env0.00Soc+1.81Gov+1.32

CSPC Pharmaceutical Group and AstraZeneca signed a joint venture contract to build a new-generation biologics manufacturing facility in Shijiazhuang, China. The JV combines CSPC’s AI-driven GMP system and manufacturing capabilities with AstraZeneca’s global quality and supply chain expertise, starting with biologics drug substances. The firms also cite a June 2025 research collaboration, with AstraZeneca paying $110 million upfront and offering milestone payments up to billions.

Coverage (4)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro